Opposing Roles of Type I Interferons in Cancer Immunity

被引:114
|
作者
Boukhaled, Giselle M. [1 ,2 ]
Harding, Shane [1 ,2 ,3 ,4 ]
Brooks, David G. [1 ,2 ]
机构
[1] Univ Hlth Network Toronto, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada
[3] Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada
[4] Univ Toronto, Dept Radiat Oncol, Toronto, ON M5S 1A8, Canada
来源
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 | 2021年 / 16卷
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
type I interferon; IFN-I; cancer immunology; hallmarks of cancer; immunotherapy; IFN-stimulated gene; ISG; CD8; T-CELLS; ENDOTHELIAL GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; DENDRITIC CELLS; CHECKPOINT BLOCKADE; PD-1; BLOCKADE; STAGE-III; INDOLEAMINE 2,3-DIOXYGENASE; MAINTENANCE TREATMENT; COLORECTAL-CANCER;
D O I
10.1146/annurev-pathol-031920-093932
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The immune system is tasked with identifying malignant cells to eliminate or prevent cancer spread. This involves a complex orchestration of many immune cell types that together recognize different aspects of tumor transformation and growth. In response, tumors have developed mechanisms to circumvent immune attack. Type I interferons (IFN-Is) are a class of proinflammatory cytokines produced in response to viruses and other environmental stressors. IFN-Is are also emerging as essential drivers of antitumor immunity, potently stimulating the ability of immune cells to eliminate tumor cells. However, a more complicated role for IFN-Is has arisen, as prolonged stimulation can promote feedback inhibitory mechanisms that contribute to immune exhaustion and other deleterious effects that directly or indirectly permit cancer cells to escape immune clearance. We review the fundamental and opposing functions of IFN-Is that modulate tumor growth and impact immune function and ultimately how these functions can be harnessed for the design of new cancer therapies.
引用
收藏
页码:167 / 198
页数:32
相关论文
共 50 条
  • [21] A critical function for type I interferons in cancer immunoediting
    Dunn, GP
    Bruce, AT
    Sheehan, KCF
    Shankaran, V
    Uppaluri, R
    Bui, JD
    Diamond, MS
    Koebel, CM
    Arthur, C
    White, JM
    Schreiber, RD
    NATURE IMMUNOLOGY, 2005, 6 (07) : 722 - 729
  • [22] A critical function for type I interferons in cancer immunoediting
    Gavin P Dunn
    Allen T Bruce
    Kathleen C F Sheehan
    Vijay Shankaran
    Ravindra Uppaluri
    Jack D Bui
    Mark S Diamond
    Catherine M Koebel
    Cora Arthur
    J Michael White
    Robert D Schreiber
    Nature Immunology, 2005, 6 : 722 - 729
  • [23] Type I interferons and dendritic cells in cancer immunotherapy
    Sprooten, Jenny
    Agostinis, Patrizia
    Garg, Abhishek D.
    IMMUNOBIOLOGY OF DENDRITIC CELLS, PT A, 2019, 348 : 217 - 262
  • [24] Type I, II, and III Interferons: Regulating Immunity to Mycobacterium tuberculosis Infection
    Maja Travar
    Miroslav Petkovic
    Antonija Verhaz
    Archivum Immunologiae et Therapiae Experimentalis, 2016, 64 : 19 - 31
  • [25] Type I, II, and III Interferons: Regulating Immunity to Mycobacterium tuberculosis Infection
    Travar, Maja
    Petkovic, Miroslav
    Verhaz, Antonija
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2016, 64 (01) : 19 - 31
  • [26] Opposing roles of eosinophils in cancer
    Simon, Sonja C. S.
    Utikal, Jochen
    Umansky, Viktor
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (05) : 823 - 833
  • [27] Opposing roles of eosinophils in cancer
    Sonja C. S. Simon
    Jochen Utikal
    Viktor Umansky
    Cancer Immunology, Immunotherapy, 2019, 68 : 823 - 833
  • [28] Role of type I and type III interferons in intestinal immunity to homologous and heterologous rotavirus infection
    Lin, Jian-Da
    Feng, Ningguo
    Sen, Adrish
    Man, Murugabaskar
    Tseng, Hsiang-Chi
    McElrath, Constance
    Durbin, Russell K.
    Greenberg, Harry B.
    Durbin, Joan E.
    Kotenko, Sergei V.
    CYTOKINE, 2015, 76 (01) : 87 - 87
  • [29] Type I Interferons and Natural Killer Cell Regulation in Cancer
    Mueller, Lena
    Aigner, Petra
    Stoiber, Dagmar
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [30] The added value of type I interferons to cytotoxic treatments of cancer
    Bracci, Laura
    Sistigu, Antonella
    Proietti, Enrico
    Moschella, Federica
    CYTOKINE & GROWTH FACTOR REVIEWS, 2017, 36 : 89 - 97